(lp0
S'Insider Trading Activity Arca Biopharma Inc   Director Bought ... Market Exclusive - Mar 28, 2017 On 2/4/2014 Riley Mccormack, Major Shareholder, bought 1,000,000 with an average share price of $1.70 per share and the total transaction amounting to $1,700,000.00.'
p1
aS"Arca Biopharma Inc  Announces The Enrollment Of The Randomized ... Journal Transcript - Mar 8, 2017 Arca Biopharma Inc , announced that 175 patients have been randomized into GENETIC-AF. It's a unique design Phase 2B/3 clinical trial for the evaluation of a new drug - Gencaro (bucindolol hydrochloride, a beta blocker and a mild&nbsp;..."
p2
aS'ARCA biopharma Announces Fiscal Year 2016 Financial Results and Provides ... Yahoo Finance - Mar 21, 2017 ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the year ended December 31, 2016, and&nbsp;...ARCA biopharma, Inc.  Files An 8-K Results of Operations and ... - Market Exclusive'
p3
aS"Arca Biopharma Inc  Director Robert E. Conway Purchases 25000 Shares Chaffey Breeze - 14 hours ago Arca Biopharma logo Arca Biopharma Inc  Director Robert E. Conway purchased 25,000 shares of the company's stock in a transaction dated Friday, March 24th.Arca Biopharma, Inc.  Files Form 4 Insider Buying : Robert E Conway Buys ... - Energy IndexRevenue Update on Arca Biopharma Inc - Money Flow Index & Trends"
p4
aS'Why Arca Biopharma Is A Buy Seeking Alpha - Jan 14, 2014 Arca Biopharma  is a pre-revenue company that has patents through 2029 covering the drug Gencaro .'
p5
aS'Arca Biopharma Inc  Announces 175th Patient Randomized into the ... Journal Transcript - Mar 7, 2017 Arca Biopharma Inc , a biopharmaceutical company that develops genetically-oriented therapies meant for treatment of cardiovascular diseases has announced randomizing the GENETIC-AF.ARCA Biopharma, Inc.  Broker Price Targets For The Coming Week - Fiscal Standard'
p6
aS'Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial Business Wire  - Jan 18, 2017 WESTMINSTER, Colo.----ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the&nbsp;...'
p7
aS'ARCA biopharma Announces 175th Patient Randomized into the GENETIC-AF Phase 2B ... Yahoo Finance - Mar 6, 2017 ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the 175th patient has been randomized into GENETIC-AF,&nbsp;...'
p8
aS'ARCA biopharma, Inc.  Files An 8-K Departure of Directors or ... Market Exclusive - Mar 1, 2017 ARCA biopharma, Inc.  Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.'
p9
aS"Insider Trading at Arca Biopharma Inc? BBNS - Mar 28, 2017 Enter your email address below to receive a concise daily summary of the latest insider trades and other news for Arca Biopharma Inc and related companies with MarketBeat.com's FREE daily insider trades newsletter.A Director at Arca Biopharma  is Buying Shares - Analyst Ratings"
p10
a.